(S)-3-Methoxy-1-phenylethylamine (CAS 82796-69-8) Market – View in Detailed Research Report

MARKET INSIGHTS

The global (S)-3-Methoxy-1-phenylethylamine (CAS 82796-69-8) market size was valued at USD 28.4 million in 2025. The market is projected to grow from USD 30.1 million in 2026 to USD 54.7 million by 2034, exhibiting a CAGR of 6.9% during the forecast period.

(S)-3-Methoxy-1-phenylethylamine (CAS 82796-69-8) is a chiral phenethylamine derivative characterized by a methoxy substituent at the meta position of the phenyl ring and a stereogenic center at the alpha carbon in the (S)-configuration. This compound serves as a valuable chiral building block and intermediate in the synthesis of pharmaceuticals, agrochemicals, and fine chemicals, particularly in the development of enantiomerically pure active pharmaceutical ingredients (APIs).

The market is steadily gaining traction, driven by the expanding demand for chiral intermediates in asymmetric synthesis and the pharmaceutical industry’s growing emphasis on enantioselective drug development. Furthermore, increasing regulatory pressure to produce single‑enantiomer drugs with improved efficacy and reduced side effects continues to elevate the compound’s relevance. Sigma‑Aldrich (Merck KGaA), TCI Chemicals, and Combi‑Blocks are among the prominent suppliers actively serving the global research and specialty chemicals market for this compound.

Top 10 Companies

1️⃣ Sigma‑Aldrich (Merck KGaA)

Headquarters: Darmstadt, Germany
Key Offering: Pharmaceutical‑grade (S)-3‑Methoxy‑1‑phenylethylamine and related chiral intermediates

Sigma‑Aldrich, part of Merck KGaA, is a leading global supplier of fine chemicals and reagents. Their extensive product portfolio includes high‑purity chiral intermediates used in API synthesis, providing reliable sourcing for pharmaceutical manufacturers worldwide.

Sustainability & Growth Initiatives:

• Investment in advanced asymmetric catalysis to improve enantiomeric excess and reduce waste
• Expansion of GMP‑certified production lines for chiral intermediates
• Partnerships with academic institutions to develop greener synthetic routes

2️⃣ TCI Chemicals

Headquarters: Tokyo, Japan
Key Offering: High‑purity chiral building blocks for pharmaceutical and agrochemical applications

TCI Chemicals specializes in the supply of fine chemicals, including chiral amines. They offer a broad range of (S)-configured intermediates with stringent purity specifications suitable for API development.

Sustainability & Growth Initiatives:

• Implementation of energy‑efficient reactors for chiral synthesis
• Use of renewable feedstocks for chiral building blocks
• Continuous improvement of chiral resolution processes to lower environmental impact

3️⃣ Combi‑Blocks Inc.

Headquarters: Irvine, USA
Key Offering: Custom synthesis and bulk supply of enantiomerically pure (S)-3‑Methoxy‑1‑phenylethylamine

Combi‑Blocks provides tailored synthesis solutions for pharmaceutical companies, delivering high‑purity chiral intermediates with rapid turnaround times.

Sustainability & Growth Initiatives:

• Development of scalable biocatalytic routes for chiral amines
• Investment in digital platforms for on‑demand synthesis requests
• Commitment to reducing solvent usage through process optimization

4️⃣ Alfa Chemistry

Headquarters: Chicago, USA
Key Offering: Research‑grade and pharmaceutical‑grade (S)-3‑Methoxy‑1‑phenylethylamine

Alfa Chemistry offers a range of chiral intermediates with strict quality control, catering to both academic research and industrial API development.

Sustainability & Growth Initiatives:

• Implementation of green chemistry principles in synthesis protocols
• Expansion of GMP‑certified production lines for chiral intermediates
• Collaboration with universities to explore novel asymmetric catalysts

5️⃣ Ambeed Inc.

Headquarters: Los Angeles, USA / Shanghai, China
Key Offering: Custom synthesis and supply of enantiomerically pure (S)-3‑Methoxy‑1‑phenylethylamine

Ambeed combines expertise in both Western and Asian markets to provide flexible supply solutions for chiral intermediates.

Sustainability & Growth Initiatives:

• Use of renewable energy sources in manufacturing facilities
• Development of low‑toxicity synthetic routes
• Partnerships with global CROs for early‑stage drug discovery

6️⃣ Hairui Chemical

Headquarters: Wuhan, China
Key Offering: High‑purity (S)-3‑Methoxy‑1‑phenylethylamine for pharmaceutical and specialty chemical applications

Hairui Chemical focuses on large‑scale production of chiral intermediates with strict quality assurance, serving both domestic and international markets.

Sustainability & Growth Initiatives:

• Investment in advanced chiral resolution technologies
• Implementation of ISO‑9001 and GMP compliance across facilities
• Research into cost‑effective enzymatic synthesis routes

7️⃣ Acrotein Chembio Inc.

Headquarters: Shenzhen, China
Key Offering: Research‑grade and pharmaceutical‑grade (S)-3‑Methoxy‑1‑phenylethylamine

Acrotein Chembio provides high‑purity chiral intermediates for drug discovery and development, with a focus on rapid delivery to CROs and pharmaceutical companies.

Sustainability & Growth Initiatives:

• Use of green solvents in chiral synthesis
• Development of modular synthesis platforms for scalability
• Collaboration with academic research centers for novel catalyst development

8️⃣ Wuhan Fortuna Chemical Co., Ltd.

Headquarters: Wuhan, China
Key Offering: Bulk supply of (S)-3‑Methoxy‑1‑phenylethylamine for API manufacturing

Wuhan Fortuna specializes in large‑volume production of chiral intermediates with GMP certification, ensuring consistent supply for global pharmaceutical manufacturers.

Sustainability & Growth Initiatives:

• Implementation of closed‑loop water recycling systems
• Optimization of reaction conditions to reduce energy consumption
• Investment in continuous flow synthesis technologies

9️⃣ Enamine

Headquarters: Ljubljana, Slovenia
Key Offering: Custom synthesis and bulk supply of enantiomerically pure (S)-3‑Methoxy‑1‑phenylethylamine

Enamine offers flexible synthesis solutions and a broad portfolio of chiral building blocks, supporting both early‑stage research and late‑stage API production.

Sustainability & Growth Initiatives:

• Development of biocatalytic processes for chiral amines
• Adoption of digital chemistry platforms for on‑demand synthesis
• Commitment to reducing carbon footprint across manufacturing sites

🔟 Merck KGaA (Sigma‑Aldrich)

Headquarters: Darmstadt, Germany
Key Offering: Comprehensive portfolio of chiral intermediates, including (S)-3‑Methoxy‑1‑phenylethylamine, with GMP‑certified production

Merck KGaA, through its Sigma‑Aldrich brand, remains a dominant player in the fine chemical market, providing high‑quality chiral building blocks for pharmaceutical development.

Sustainability & Growth Initiatives:

• Investment in green chemistry initiatives and renewable feedstocks
• Expansion of GMP facilities to meet increasing demand for chiral intermediates
• Collaborations with industry partners to develop more efficient asymmetric synthesis routes

Download FREE Sample Report: (S)-3-Methoxy-1-phenylethylamine (CAS 82796-69-8) Market – View in Detailed Research Report

Get Full Report: (S)-3-Methoxy-1-phenylethylamine (CAS 82796-69-8) Market – View in Detailed Research Report

OUTLOOK

The (S)-3‑Methoxy‑1‑phenylethylamine market is expected to continue its robust growth trajectory, driven by the expanding pipeline of chiral drug candidates and the increasing adoption of enantioselective manufacturing processes. Pharmaceutical companies worldwide are prioritizing single‑enantiomer drugs to improve therapeutic efficacy and reduce side effects, creating a sustained demand for high‑purity chiral intermediates. Additionally, advancements in biocatalysis and green chemistry are lowering production costs and enhancing the environmental sustainability of chiral synthesis, further boosting market adoption.

FUTURE TRENDS

• Rising demand for chiral building blocks in CNS, cardiovascular, and metabolic disease drug development
• Growth of contract research and development organizations driving early‑stage synthesis of chiral intermediates
• Increasing regulatory emphasis on stereochemical purity and single‑enantiomer approvals
• Expansion of digital chemistry platforms enabling on‑demand synthesis of specialty chiral compounds
• Adoption of biocatalytic and enzyme‑based synthesis routes to reduce cost and environmental impact